Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. - Wikidata - awgldk - TriplyDB

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

http://www.wikidata.org/entity/Q42971644

about

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Immune Modulation in Hematologic Malignancies Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Lack of in vitro antimicrosporidian activity of thalidomide An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome The next generation of novel therapies for the management of relapsed multiple myeloma.Emerging drugs for chronic lymphocytic leukaemia.Selective leukemic-cell killing by a novel functional class of thalidomide analogs Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Thalidomide for the treatment of idiopathic myelofibrosis.Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).Immunomodulation by thalidomide and thalidomide analogues Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Thalidomide: a remarkable comeback.Update on therapy--thalidomide in the treatment of lupus.The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.Immunotherapeutic and antitumour potential of thalidomide analogues.Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Small therapeutic molecules for the treatment of inflammatory bowel disease Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Thalidomide as an anti-cancer agent.Thalidomide: an old drug with new clinical applications.Novel therapeutic approaches for pulmonary fibrosis.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Thalidomide for erythema nodosum leprosum and other applications.Thalidomide: a new anticancer drug?Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.

P2860

Q24605861-5AC8A102-77B2-4143-AD64-01ACE4FD6372 Q24651269-F4AA16DF-B0C2-44B2-90C0-32110D581F99 Q24685895-82878327-3C9E-45C7-B11E-90DA8B49C7DE Q26770391-192C486B-E2BF-4829-8678-6B0574365D05 Q26796307-F5566E88-74E5-47AA-82F5-A73A2BF7F6EA Q28192646-93FF9C42-DCC9-4A9B-90DE-509AC0716D63 Q28303091-C51A0D39-4D04-456B-8000-E5D712975094 Q28343553-C643ED52-098B-4ABE-A266-171B5520C6FB Q28472171-E8D7E7C0-A448-48FF-AF08-358B81216551 Q30248534-E213474E-16DF-44F4-8648-BCE2B835A878 Q30353154-6D0A0B9E-836B-4237-A805-1439409CCBA2 Q30479632-6942C381-19E3-4827-AE21-213EDCFB5227 Q33322921-2498DF0F-5CAA-4994-A3CE-1777C27E03F8 Q33359542-7680F1FD-E81B-447B-9BD2-ED95BE5D4F43 Q33360969-6BC30A88-FCC8-4967-8EDD-A3147F75C8D8 Q33364235-1009C697-9D7D-404D-916B-58785CC212E3 Q33391803-BDD121FB-7B85-4AEE-8FA6-7DA05D442BE9 Q33436535-6BCE7368-FB0C-44B3-8E59-7F76E3D335CB Q33611998-5EE2A4C5-4A4C-46A8-8952-229C07D25E01 Q33655628-29F2150F-FD6C-451B-BB3B-36FB7E4F70E2 Q33782386-4A7F253F-ABF6-46F9-89BF-E20F8779C599 Q34109028-91BDF3CA-5C57-47F3-BD26-AFA630A55E45 Q34109469-11ADB468-4362-4204-A2A2-615C4C2FE9CF Q34165935-366E7B40-FB56-4940-8C44-2E97FF483FA3 Q34182143-602D4184-6591-47C4-A4C9-342CBA76D482 Q34227018-819DF699-2A29-485C-923C-DBD650474945 Q34289226-F6C04694-E3D9-4645-95CA-B70DC152A40B Q34451909-8D685C8B-7833-4958-8163-C21E86925BC4 Q34454532-6D3D7940-02B8-4528-A465-21E282014392 Q34600992-159F685A-D1C5-4610-9629-3E728617FBEF Q34666858-74D5FECA-56F1-4BAA-8E17-C596E299EDB6 Q34775475-DC5912BC-4908-4A60-9CB3-6920B1DD4796 Q34778074-14EB92FC-09CB-43D5-8311-58A5DE76F69F Q34798767-C53D402E-BBED-4034-8B88-4C6877EEFF5A Q34903224-C13CF7AE-5C47-4249-A502-913F99095AE0 Q35026302-AA8B5B23-6DE9-4768-AFB3-FA46D34FD90A Q35101473-4083B75C-4B5F-49CA-B71D-A954E399EE4F Q35164773-8819A67B-6FDA-4607-9317-B790B96B6280 Q35171777-BE2DDC2C-A845-469A-BD78-36260A9F04CE Q35175287-26A4C626-6006-4E80-A1BE-1BD83120D41A

P2860

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

http://www.wikidata.org/entity/Q42971644

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@en

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@nl

type

label

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@en

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@nl

prefLabel

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@en

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@nl

P1433

Q42971644-80942332-6C0B-42BC-966D-5E6B5D14F27F

P1476

Q42971644-FD9EED8A-8CBE-47F0-8220-C3FFAC5CEEBD

P2093

Q42971644-596AEB30-9563-4CF3-934C-F9EBE8875EB2

Q42971644-BD49A9BA-0C8D-4FC9-8ACD-48D620514834

Q42971644-C576C861-E85D-455D-B634-7942C6B8166E

Q42971644-E31060AE-CC8C-4910-9C96-EBDB7BA83DFD

P2860

Q42971644-27629B5D-2122-4466-A01A-FC8A1FC50990

Q42971644-27F2389E-8E26-4BF8-9872-7AAC32E449D9

Q42971644-2DCD2FB6-600E-4B4A-926B-3C19CF61D681

Q42971644-3676C315-83DC-478E-8000-6CBA0096EDA8

Q42971644-36C52A38-8757-4171-A21F-0D66C4BAE229

Q42971644-42E598CF-747C-435F-917B-B8F4B4E13BBA

Q42971644-57010865-D294-4E98-BB04-E8C30D469312

Q42971644-63261330-5B10-4924-B532-945074B80CE4

Q42971644-641CAB03-7E9C-412C-A0CD-1539265F0717

Q42971644-6B2F77DB-0D5D-4AE9-85F7-5B189BC42459

P304

Q42971644-592E6313-980A-4718-BB55-FA3BABD7EC84

P31

Q42971644-E9C1A577-BAA6-428B-90B8-1874991DB9EF

P356

Q42971644-64E39B8E-2821-4B71-861B-8854F0C34023

P407

Q42971644-7513DF06-AB52-45E3-BD10-55EB5E8E744B

P433

Q42971644-54205CDD-E926-4229-8BF2-46E9A3C917CB

P478

Q42971644-D1800D55-4F68-46C1-B070-127050CE6364

P577

Q42971644-C34F005A-CCBD-4C6D-9002-710F7F4DD952

P5875

Q42971644-4A1AD725-F9F6-43A1-BFA3-307FC2F283ED

P698

Q42971644-A517633B-B0AF-4224-9A13-594E3D41C869

P921

Q42971644-625B6687-55BE-44C6-81C9-F72218E1EA0D

Q42971644-CBFAE6F2-8308-4AD4-A0C6-0ACD7C04D90B

P932

Q42971644-BD90B4FF-E821-4EF4-8939-568E9BF638F8

P356

JEM.187.11.1885

P1433

Journal of Experimental Medicine

P1476

Thalidomide costimulates prima ...... responses in the CD8+ subset.

@en

P2093

G Kaplan

http://www.w3.org/2001/XMLSchema#string

L G Corral

http://www.w3.org/2001/XMLSchema#string

M Albert

http://www.w3.org/2001/XMLSchema#string

P A Haslett

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Stigma variations: observations on suppressor T cells and leprosy.

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation.

Does thalidomide affect IL-2 response and production?

Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.

P304

1885-1892

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.187.11.1885

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

1998-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13676214

http://www.w3.org/2001/XMLSchema#string

P698

9607928

http://www.w3.org/2001/XMLSchema#string

P921

P932

2212313

http://www.w3.org/2001/XMLSchema#string